ASLAN Pharmaceuticals today announced that new pre-clinical data on varlitinib’s activity in triple negative breast cancer (TNBC) cell lines have been published online in Cancers, a peer-reviewed oncology journal. The data suggest that HER-family signalling plays an important role in TNBC progression and that pan-HER inhibition is potentially an effective treatment for TNBC patients.

The publication is available to view via https://www.mdpi.com/2072-6694/11/1/105.

For more information, please refer to the English or Chinese press release.